Management of Hematoma in Hemophilia A Patient on Emicizumab and Advate Prophylaxis
For a patient on emicizumab prophylaxis who develops a hematoma, immediately treat with recombinant Factor VIIa (rFVIIa) at 90 μg/kg every 3 hours for 3 doses OR a single dose of 270 μg/kg, NOT activated prothrombin complex concentrate (aPCC), due to thrombotic risk when combined with emicizumab 1.
Immediate Laboratory Assessment
Critical Labs to Order:
Emicizumab plasma level using modified one-stage assay (mOSA) with higher sample pre-dilution and emicizumab-specific calibration 2, 3
FVIII inhibitor titer using chromogenic assay with bovine reagents 5, 3
Complete blood count to assess for anemia from ongoing bleeding 7
If FVIII was recently administered: measure FVIII activity using chromogenic method with non-human (bovine) reagents only 5
- Standard FVIII assays cannot distinguish between emicizumab and infused FVIII 4
Optional Global Hemostasis Assessment:
Thrombin generation assay (TGA) using 1 pM tissue factor plus 1 μM phospholipids 8
- Thrombin peak and endogenous thrombin potential (ETP) correlate with emicizumab levels
- Target values: thrombin peak or ETP corresponding to ≥40 μg/mL emicizumab
Thromboelastometry without exogenous triggers 8
- Clotting time correlates with emicizumab activity
Clinical Assessment
Hematoma Characteristics:
- Size and location: measure dimensions, document expansion
- Severity classification per Advate labeling 9:
- Moderate: muscle bleeding, definite hemarthrosis, known trauma → target FVIII 30-60% (15-30 IU/kg)
- Major: significant GI, intracranial, intra-abdominal, intrathoracic, retroperitoneal bleeding, fractures → target FVIII 60-100% (30-50 IU/kg)
Neurovascular Status:
- Compartment syndrome signs (pain out of proportion, paresthesias, pallor, pulselessness)
- Nerve compression symptoms
- Vascular compromise
Treatment Algorithm
Step 1: Immediate Hemostatic Management
Primary Treatment (Patient on Emicizumab):
- Recombinant FVIIa (eptacog alfa): 90 μg/kg IV every 3 hours × 3 doses 1
If Inhibitor Titer is Low (<2 BU/mL):
- Consider recombinant FVIII (Advate) at higher doses 1, 7
- Dose per Advate labeling: 15-30 IU/kg for moderate bleeds, 30-50 IU/kg for major bleeds 9
- Monitor FVIII activity using chromogenic assay with bovine reagents 5, 3
- Case report demonstrates successful FVIII use when inhibitor decreased to 0.6 BU/mL on emicizumab 7
Step 2: Dosing Frequency
- For moderate hematomas: repeat dosing every 12-24 hours until resolved (approximately 3+ days) 9
- For major hematomas: repeat every 8-24 hours until bleeding resolved 9
- Younger patients (<6 years): may require more frequent dosing (every 6-12 hours for major bleeds) 9
Step 3: Monitoring Response
- Serial clinical assessment: hematoma size, pain, function
- Hemoglobin/hematocrit: every 6-12 hours initially if significant bleeding
- Do NOT use standard APTT or FVIII one-stage assays - emicizumab causes false results 2, 5
Step 4: Inhibitor Surveillance
- Repeat inhibitor testing using chromogenic assay with bovine reagents at:
- 1 week post-treatment
- 2 weeks post-treatment
- Monthly for first 3 months if FVIII was used 6
- Inhibitors can develop or increase even on emicizumab prophylaxis 7, 6
- If inhibitor rises significantly, continue emicizumab but switch breakthrough bleed management to rFVIIa exclusively 7
Critical Pitfalls to Avoid
Never use aPCC in patients on emicizumab - documented thrombotic complications 1
Do not rely on standard coagulation tests - APTT will be falsely normalized by emicizumab 2, 5
Do not use standard Bethesda assay for inhibitor testing - will be falsely negative 3
Do not assume emicizumab alone is sufficient - breakthrough bleeds require additional hemostatic therapy 1, 6
Do not skip inhibitor surveillance - inhibitors can develop silently on emicizumab prophylaxis, requiring change in bleed management strategy 6